Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is among the most treatment-resistant malignancies because of its dense desmoplastic stroma, metabolic plasticity, and immunosuppressive tumor microenvironment. Lactate, once viewed primarily as a glycolytic byproduct, also acts as an epigenetic signal through histone lactylation, particularly histone H3 lysine 18 lactylation (H3K18la). Recent PDAC studies implicate H3K18la in three distinct reported mechanisms: a glycolysis-H3K18la-TTK/BUB1B positive-feedback loop, an H3K18la-ACAT2-cholesterol axis that promotes macrophage-mediated immunosuppression, and a PCAF-H3K18la-CXCL1 pathway that recruits neutrophils and supports immune escape. Together, these findings identify the lactate-lactylation axis as a potential therapeutic vulnerability in PDAC. This review synthesizes evidence linking lactate metabolism, histone lactylation, immune remodeling, and therapeutic resistance, with emphasis on RNA-based interventions. We evaluate small interfering RNA, microRNA-based, antisense, and other non-coding RNA strategies directed at lactate production and transport, chromatin writers and erasers, and axis-specific effectors. We also examine translational barriers, including nuclease degradation, renal clearance, membrane impermeability, endosomal trapping, off-target effects, and limited penetration of nanoparticles through the PDAC stroma. Integrating cancer metabolism, epigenetics, immunology, and RNA nanomedicine, this review proposes a translational framework for testing lactylation-directed RNA therapeutics in PDAC.
No takes yet. Share an insight, caveat, or question.
Wakil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: